Objective To evaluate the efficacy of erlotinib as a role in synthetic therapy on patients with advanced pancreatic cancer. Methods To retrospectively analyze clinical data of 17 pancreatic cancer patients, who took erlotinib ( lOOmg/d or 150mg/d) orally as initial treatment(2 cases) or re-treatment (15 cases) at least 1 cycle and efficacy could be evaluated as well. Results No patient achieved CR, with PR in 1 case, SD in 8 cases and PD in 8 cases, and disease control rate was 52.9% (9/17). The median progression free survival was 1.4 months (0.7-8.0 months). The median overall survival was 12.0 months (6.0-21.0 months). Grade 1 -2 rashes and no more than grade 4 hematologic toxicity were the main adverse effects with no treatment related death. Conclusion Erlotinib can be widely used in patients with advanced pancreatic cancer, either by exclusive use or combined with other treatment , and it is a valid choice for patients with advanced pancreatic cancer. Furthermore, active synthetic therapy can greatly improve the overall survival of advanced pancreatic cancer.%目的 观察厄洛替尼在晚期胰腺癌综合治疗中的临床疗效.方法 回顾性分析17例经厄洛替尼初治(2例)和复治(15例)的晚期胰腺癌患者的临床资料,所有患者口服厄洛替尼(100mg/日或150mg/日)至少1个周期.结果 无1例患者达CR,获PR 1例,SD 8例,PD 8例,疾病控制率为52.9％ (9/17)；中位无进展生存期为1.4个月(0.7 ～8.0个月)；中位生存期为12.0个月(6.0～21.0个月).主要不良反应为1～2级皮疹和4级以下血液学毒性,未发生治疗相关性死亡.结论 厄洛替尼在晚期胰腺癌的综合治疗中具有广泛的应用价值,可单药维持或与放疗、化疗等联合应用,是晚期胰腺癌患者的有效选择之一；积极的综合治疗能显著延长晚期胰腺癌患者的生存时间.
展开▼
